By Dr. Priti Nanda Sibal, Functional Medicine & Root-Cause Health Expert

For years, weight loss was dominated by diets, calorie counting and exercise plans. Then came a new generation of medicines that changed the conversation almost overnight.

GLP-1-based weight loss drugs such as Ozempic, Wegovy and Mounjaro have become some of the most discussed medicines in obesity and metabolic health. Now, another generation of obesity treatments is emerging, promising even greater possibilities.

In September 2026, Novo Nordisk announced new Phase 3 results for CagriSema, an investigational once-weekly combination of cagrilintide and semaglutide. In one trial involving adults with type 2 diabetes, participants receiving CagriSema 1.0 mg/1.0 mg achieved an estimated average weight loss of 12.4%, compared with 9.1% among those receiving tirzepatide 5 mg. Another trial reported 21% weight reduction with CagriSema versus 2% with placebo.

The drug remains investigational, but the direction of obesity medicine is becoming clear: the race is moving beyond the first generation of GLP-1 weight loss injections.

But there is another question worth asking.

Is Losing Weight the Same as Becoming Metabolically Healthy?

Not necessarily.

Body weight is one marker of health. It is not the complete picture.

Metabolic health involves several interconnected factors, including blood glucose regulation, insulin sensitivity, visceral fat, blood pressure, lipid levels, muscle health, nutrition, sleep and physical activity.

This becomes especially important when medications significantly reduce appetite and food intake.

A 2026 Indian expert consensus on nutrition during GLP-1-based therapies highlighted the importance of nutritional assessment, adequate high-quality protein, micronutrients, hydration, sustainable lifestyle practices and resistance exercise. The recommendations are particularly relevant for Indians because of dietary diversity and the risk of sarcopenia, or loss of muscle mass.

Recent research has also shifted attention from simply asking “How much weight did someone lose?” to “What kind of weight did they lose?”

Significant weight loss can include both fat and lean mass. A 2026 meta-analysis found that resistance training, adequate protein intake and body-composition monitoring can help preserve muscle during weight-loss treatment.

That distinction matters.

As I often tell my patients:

“The goal should never be to make the weighing scale smaller at the cost of making the body weaker. Sustainable weight management means improving metabolic health while protecting muscle, nutrition and long-term function.” — Dr. Priti Nanda Sibal

The Future May Be Medication Plus Metabolic Care

GLP-1 and newer obesity medicines should not be reduced to either “miracle injections” or “dangerous shortcuts.”

They are medical therapies that may be appropriate for selected patients under qualified medical supervision.

The bigger opportunity is to stop treating medication and lifestyle as competing approaches.

Someone receiving obesity treatment may still need appropriate nutrition, sufficient protein, resistance exercise, good sleep, management of gastrointestinal side effects and monitoring of metabolic health.

And what happens after treatment matters too.

The recent Indian consensus notes that sustained nutritional support after discontinuing GLP-1-based therapy may help prevent metabolic rebound.

As the next generation of weight-loss medicines arrives, healthcare needs to evolve with it.

The future of obesity care should not be defined by who loses the most kilograms the fastest.

It should be defined by whether we can help people lose excess fat, preserve muscle, improve metabolic health and build results that can be sustained.

Because ultimately, weight loss is an outcome. Better health is the objective.